BALPHARMA vs LASA: Stock Comparison
BALPHARMA is the larger company by market capitalisation. BALPHARMA shows a higher ROE, a higher dividend yield and faster revenue growth, while LASA shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALPHARMA leads 7; LASA leads 2 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALPHARMA | LASA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BALPHARMA | LASA |
|---|---|---|
| Live Price | ₹106.79 | ₹6.52 |
| Day Change | 0.99% | -2.54% |
| Volume | 25,522 | 46,913 |
| 52-Week High | ₹124.6 | ₹12.48 |
| 52-Week Low | ₹60 | ₹5.67 |
| Distance from 52W High | -14.29% | -47.76% |
Valuation
| Metric | BALPHARMA | LASA |
|---|---|---|
| Market Cap | ₹134 Cr | ₹27 Cr |
| EPS | ₹0.71 | ₹-0.71 |
| Book Value | ₹51.66 | ₹9.9 |
| Dividend Yield | 1.36% | 0% |
Growth
| Metric | BALPHARMA | LASA |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.7% | 0% |
| EPS Growth (TTM YoY) | -33.5% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BALPHARMA | LASA |
|---|---|---|
| ROE | 6.49% | -68.7% |
| ROCE | 9.07% | -57.92% |
| Net Margin | 2.02% | -135.6% |
| Operating Margin | 7.46% | -136.12% |
| Debt to Equity | 1.48x | 0.2x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BALPHARMA | LASA |
|---|---|---|
| Promoter Holding | 46.74% | 53.65% |
| FII Holding | 0.28%▲ 0.13 pp | 0% |
| DII Holding | 0% | 0% |
| Public Holding | 48.87%▼ 0.12 pp | 46.35% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and LASA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.